Testing a new drug for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has spread or can't be fully removed by surgery.
- You've already had treatment with an immunotherapy drug (like Keytruda or Tecentriq), platinum chemotherapy, and another targeted drug called enfortumab vedotin (Padcev).
- You've had no more than 2 prior cancer treatments.
- Your cancer has gotten worse during or after your last treatment.
- You are well enough to take care of yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial compares two antibody-drug conjugates (a type of targeted therapy that delivers chemotherapy directly to cancer cells) for advanced urothelial cancer. It aims to find a safer and more effective treatment option for patients with this disease.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.